TNFR2/CD120b Polyklonaler Antikörper

TNFR2/CD120b Polyklonal Antikörper für WB, IHC, IF/ICC, Indirect ELISA

Wirt / Isotyp

Kaninchen / IgG

Getestete Reaktivität

human

Anwendung

WB, IHC, IF/ICC, Indirect ELISA

Konjugation

Unkonjugiert

Kat-Nr. : 28746-1-PBS

Synonyme

TNFR2 / TNFRSF1B, TNFRSF1B, CD120b, Etanercept, p75



Geprüfte Anwendungen

Produktinformation

28746-1-PBS bindet in WB, IHC, IF/ICC, Indirect ELISA TNFR2/CD120b und zeigt Reaktivität mit human

Getestete Reaktivität human
Wirt / Isotyp Kaninchen / IgG
Klonalität Polyklonal
Typ Antikörper
Immunogen TNFR2/CD120b fusion protein Ag30490
Vollständiger Name tumor necrosis factor receptor superfamily, member 1B
Berechnetes Molekulargewicht 48 kDa
Beobachtetes Molekulargewicht 75 kDa, 65 kDa
GenBank-ZugangsnummerBC052977
Gene symbol TNFR2
Gene ID (NCBI) 7133
Konjugation Unkonjugiert
Form Liquid
Reinigungsmethode Antigen-Affinitätsreinigung
Lagerungspuffer PBS only
LagerungsbedingungenStore at -80°C. 20ul Größen enthalten 0,1% BSA.

Hintergrundinformationen

Tumor necrosis factor-alpha (TNFA/TNFSF2) is a multifunctional cytokine that plays a key role in regulating inflammation, immune functions, host defense, and apoptosis (PMID: 16407280). TNFA signals through two distinct cell surface receptors, TNFR1 (TNFRSF1A, CD120a, p55) and TNFR2 (TNFRSF1B, CD120b, p75). TNFR1 is widely expressed, whereas TNFR2 exhibits more restricted expression, being found on CD4 and CD8 T lymphocytes, endothelial cells, microglia, oligodendrocytes, neuron subtypes, cardiac myocytes, thymocytes and human mesenchymal stem cells (PMID: 20489699; 22374304). In contrast to TNFR1, TNFR2 does not have a death domain. TNFR2 only signals for antiapoptotic reactions. However, recent evidence indicates that TNFR2 also signals to induce TRAF2 degradation (PMID: 22374304). Various defects in the TNFR2 pathway, due to polymorphisms in the TNFR2 gene, upregulated expression of TNFR2 and TNFR2 shedding, have been implicated in the pathology of several autoimmune disorders (PMID: 20489699).